GSGobinda Sarkar

Gobinda Sarkar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gobinda Sarkar has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer

    by Gobinda Sarkar, Jun Chen, Shubham Sood, Karen Fischer, Kim Kossick, Daniel Schupack, Rondell Graham, Brooke Druliner, Zahra Heydari, Lauren Helgeson, et al.

    Background and aims: Aberrations in telomere length can have important implications in cancer. Using a cohort of 1007 patients, we investigated whether leukocyte telomere length (LTL) in patients with colorectal cancer (CRC) is associated with survival. We also investigated whether some telomere maintenance genes are associated with survival in these patients. Methods: The Biobank for Gastrointestinal Health Research (BGHR), an ongoing project involving collection of biospecimens at the Mayo Clinic, was utilized to obtain data from patients diagnosed with stage II or III CRC. Blood samples were collected prior to chemotherapy/radiation and DNA was extracted for measuring median LTL. The main outcome measures were overall survival (OS) and disease-free survival (DFS) by disease stage. Results: A significant inverse relationship was observed with patient age and LTL (spearman correlation coefficient (r) = −0.48, 95%; p = 1.13 × 10−58). Females had significantly longer LTL than males (p = 3.97 × 10−5). The rs1317082 SNP in the TERC gene was significantly associated with both OS and DFS in combined stage II and stage III patients (p = 0.017 and p = 0.023, respectively). A statistically significant association of the OBFC1 SNP (rs9419958) was observed for OS for the combined stage II and stage III patients (p = 0.016). Importantly, LTL was significantly associated with both OS and DFS (p = 0.008 and 0.044 respectively) in combined stage II and stage III patients. Conclusions: Our results show that LTL is predictive of OS and DFS for stage II and III CRC patients, particularly over a longer follow-up, extending beyond five years after a diagnosis of CRC, and certain SNPs in genes involved in telomere maintenance are significantly associated with patient outcomes, independent of telomere length.

  • Open Access

    Colon Organoids as Experimental Models to Study the Effect of Micro-Nanoparticles as a Driver of Early-Onset Colon Cancer

    by Zahra Heydari, Gobinda Sarkar, Lauren Helgeson, Estela Mariel Cruz Garcia, Alexandra Ros, Khashayarsha Khazaie, Lisa Boardman

    Early-onset colorectal cancer (EOCRC) in people < 50 years of age has been rising globally, yet its causes remain unknown. Emerging evidence suggests that environmental factors, including exposure to micro-and nanoplastics (MNPs), may contribute to colorectal carcinogenesis. MNPs can enter the gastrointestinal tract through ingestion, translocate across the epithelial barrier via endocytosis or paracellular pathways, and interact directly with epithelial and immune cells. Once internalized, they may generate events associated with tumor initiation including oxidative stress, disruption of membrane integrity, pro-inflammatory signaling, and disruption of genomic and epigenomic stability. Patient-derived colorectal organoids offer a physiologically relevant and scalable 3D model that closely mimics the cellular architecture and genetic landscape of primary tumors. We highlight how organoid models can be leveraged to study the impact of MNPs on the key processes of inflammation, DNA damage, senescence, and epigenetic modifications. Furthermore, we discuss the application of organoid-based systems to model EOCRC driven by environmental exposures, including the integration of organoid platforms with high-throughput assays, omics profiling, and microfluidics to better capture MNP-induced pathogenic mechanisms. Altogether, colorectal organoids provide a powerful bridge between environmental plastic exposure and EOCRC etiology, offering a tractable platform to identify mechanistic pathways and potential biomarkers of early disease.


  • Open Access

    A Practical Guide to Developing and Troubleshooting Patient-Derived “Mini-Gut” Colorectal Organoids for Clinical Research

    by Rex Devasahayam Arokia Balaya, Zahra Heydari, Gobinda Sarkar, Estela Mariel Cruz Garcia, Jose M. de Hoyos-Vega, Eugene Krueger, Lauren Helgeson, Alexander Revzin, Alexandra Ros, Akhilesh Pandey, et al.

    Patient-derived organoids (PDOs) have emerged as powerful tools in personalized medicine applicable to both non-malignant conditions and to cancer, where they are increasingly used for personalized drug screening and precision treatment strategies in part due to their ability to replicate tumor heterogeneity. They also serve as study model systems to understand disease mechanisms, pathways, and the impact of ex vivo exposures. We present a detailed step-by-step protocol for generating organoids from normal crypts, polyps, and tumors, including methods for tissue processing, crypt isolation, culture establishment, and the transition from basolateral to apical-out polarity for co-culture and exposure-based studies. The protocol also includes immunofluorescence staining procedures for cellular characterization and quality control measures. Our standardized approach successfully generates organoids from diverse colorectal tissues with high efficiency and reproducibility. This comprehensive guide addresses common technical challenges and provides troubleshooting strategies to improve success rates across different sample types. We believe that this resource will enhance reproducibility in organoid research and expand their utility in translational applications, particularly for personalized medicine approaches in colorectal cancer.


  • Open Access

    The Role of Organoids in Advancing Colorectal Cancer Research: Insights and Future Directions

    by Zahra Heydari, Rex Devasahayam Arokia Balaya, Gobinda Sarkar, Lisa Boardman

    Organoids are three-dimensional (3D) structures that mimic the architecture and functionality of human organs, providing a novel approach to study diseases such as colorectal cancer (CRC). This review aims to explore the impact of organoids on understanding CRC and their potential use in exploring therapeutic outcomes. Colorectal cancer, characterized by the transformation of colonic epithelial cells into adenomas and carcinomas, remains one of the top causes of cancer-related morbidity and mortality worldwide. Traditional two-dimensional (2D) cell cultures fail to replicate the tumor microenvironment in an effective manner, which highlights the need for advanced 3D models. Organoids preserve the genetic and phenotypic properties of the original tumors, allowing for improved disease modeling, drug screening, and personalized medicine applications. When using patient-derived organoids (PDOs), researchers can gain insights into CRC initiation, progression, and treatment outcome. Ultimately, organoids represent an encouraging platform for improving therapeutic strategies for CRC, potentially leading to better patient outcomes through tailored treatment approaches.


  • GENE-29. DLL3 AND ETV1 ARE INACTIVATED/METHYLATED IN CIC WILD-TYPE, IDH-MUTATED, 1p/19q-CODELETED GLIOMA

    by Matthew Kosel, Daniel Lachance, Paul Decker, Thomas Kollmeyer, Alissa Caron, Kristen Drucker, Gobinda Sarkar, Andrew Knight, Chandralekha Halder, Shulan Tian, et al.

    Adult diffuse glioma that harbor IDH mutation and 1p/19q codeletion commonly have CIC mutations; however, the functional and prognostic significance of CIC mutations remains unclear. We hypothesized that when CIC is not mutated, other genes may be inactivated by hypermethylation. Identifying such genes may help to further understand the biology of 1p/19q-codeleted glioma. To test our hypothesis, we utilized a two-stage design. In the discovery stage, 72 IDH-mutated 1p/19q-codeleted tumors were utilized from TCGA (40 CIC mutated, 32 wild-type); all via Illumina 450K methylation array. In the validation stage, 43 IDH-mutated 1p/19q-codeleted tumors were utilized from Mayo Clinic (33 CIC mutated, 10 wild-type); all via Illumina 850K methylation array. All tumors also had TERT promoter mutation. Genome-wide significance (p≤5x10-8) was used in the discovery stage to identify differentially methylated probes between CIC mutated vs wild-type tumors. Seven probes reached significance in TCGA; four validated at pCIC. DLL3, located on 19q, had a mean change in beta value between CIC wild-type and mutated tumors of 0.28 (p=1.29x10-8) and 0.24 (p=0.0024) in TCGA and Mayo, respectively. ETV1, located on 7p, had a mean change in beta value of 0.30 (p=1.37x10-8) and 0.15 (p=0.00011) in TCGA and Mayo, respectively. In the 72 TCGA tumors, we observed an inverse correlation between DLL3 methylation and gene expression amongst CIC mutated and wild-type tumors; -0.42 (p=0.0063) and -0.33 (p=0.069), respectively. There was also an inverse correlation between ETV1 methylation and gene expression amongst CIC mutated and wild-type tumors; -0.68 (pDLL3 and ETV1 was downregulated in CIC wild-type vs mutated tumors (p=0.000027 and 0.0000028, respectively). We confirm that ETV1 has higher gene expression in CIC mutated vs wild-type tumors. Our results suggest that DLL3 expression is inactivated by promoter methylation in CIC wild-type 1p/19q-codeleted oligodendrogliomas; thus, DLL3 may be an alternative target gene on 19q.


  • TMOD-34. IMPROVED TREATMENT OF MELANOMA BRAIN METASTASIS USING A SYNTHETIC PEPTIDE

    by Synnove Aasen, Heidi Espedal, Christopher Florian Holte, Olivier Keunen, Tine Veronika Karlsen, Olav Tenstad, Zaynah Maherally, Hrvoje Miletic, Anne Vaag Eikeland, Habib Baghirov, et al.

    Individuals with brain metastasis usually await a poor prognosis. Even with the ongoing development of novel targeted therapies, a major impediment in the treatment of brain metastasis is delivering of drugs across the blood-brain/tumor barrier. Different strategies to accomplish temporary opening of the heterogenous blood-brain barrier have been described. Here, we report on a synthetic peptide, K16ApoE, which is able to open the blood-brain barrier for improved drug-delivery in a non-permanent manner. We carried out extensive dynamic contrast enhanced magnetic resonance imaging experiments to study the ability of the peptide to open the blood-brain barrier in healthy mice. We further performed dynamic positron emission/computer tomography, with F18-labeled albumin and IgG to validate an open blood-brain barrier after co-injecting with K16ApoE. Further, we studied the effects of the peptide on cells and tissue in vitro and in vivo. The biodistribution of the peptide was studied in healthy mice by labeling I-125 to the imidazole ring of histidine in K16ApoE and tracking the peptide in plasma and tissue. We also conducted a treatment study on BRAFV600Emutant brain metastases, where the treatment groups received K16ApoE before a BRAF inhibitor was administered, BRAF inhibitor only, K16ApoE only or vehicle. We found a peptide-induced therapeutic window at approximately 30 minutes using dynamic contrast enhanced magnetic resonance imaging. The dynamic positron emission/computer tomography showed cerebral uptake of albumin (∼67 kDa) and IgG (∼150 kDa) in healthy mice with a presumed intact blood-brain barrier. Further, we identified lysis of cells treated with K16ApoE in addition to in part endocytosis-mediated peptide uptake. In vitro blood-brain barrier modeling demonstrated endothelial and astrocyte cell layer regrowth within approximately three and 15 hours, respectively, after treatment with the peptide. We observed a significant treatment effect of co-injecting the peptide with a BRAF inhibitor on BRAF mutated brain metastases.

  • Open Access

    Peptide Carrier-Mediated Non-Covalent Delivery of Unmodified Cisplatin, Methotrexate and Other Agents via Intravenous Route to the Brain

    by Gobinda Sarkar, Geoffry L. Curran, Jann N. Sarkaria, Val J. Lowe, Robert B. Jenkins

    Rapid pre-clinical evaluation of chemotherapeutic agents against brain cancers and other neurological disorders remains largely unattained due to the presence of the blood-brain barrier (BBB), which limits transport of most therapeutic compounds to the brain. A synthetic peptide carrier, K16ApoE, was previously developed that enabled transport of target proteins to the brain by mimicking a ligand-receptor system. The peptide carrier was found to generate transient BBB permeability, which was utilized for non-covalent delivery of cisplatin, methotrexate and other compounds to the brain. Brain delivery of the chemotherapeutics and other agents was achieved either by injecting the carrier peptide and the drugs separately or as a mixture, to the femoral vein. A modification of the method comprised injection of K16ApoE pre-mixed with cetuximab, followed by injection of a ‘small-molecule’ drug. Seven-of-seven different small molecules were successfully delivered to the brain via K16ApoE. Depending on the method, brain uptake with K16ApoE was 0.72–1.1% for cisplatin and 0.58–0.92% for methotrexate (34-50-fold and 54–92 fold greater for cisplatin and methotrexate, respectively, with K16ApoE than without). Visually intense brain-uptake of Evans Blue, Light Green SF and Crocein scarlet was also achieved. Direct intracranial injection of EB show locally restricted distribution of the dye in the brain, whereas K16ApoE-mediated intravenous injection of EB resulted in the distribution of the dye throughout the brain. Experiments with insulin suggest that ligand-receptor signaling intrinsic to the BBB provides a natural means for passive transport of some molecules across the BBB. The results suggest that the carrier peptide can non-covalently transport various chemotherapeutic agents to the brain. Thus, the method offers an avenue for pre-clinical evaluation of various small and large therapeutic molecules against brain tumors and other neurological disorders.


  • Open Access

    A Carrier for Non-Covalent Delivery of Functional Beta-Galactosidase and Antibodies against Amyloid Plaques and IgM to the Brain

    by Gobinda Sarkar, Geoffry L. Curran, Eric Mahlum, Teresa Decklever, Thomas M. Wengenack, Anthony Blahnik, Bridget Hoesley, Val J. Lowe, Joseph F. Poduslo, Robert B. Jenkins

    Therapeutic intervention of numerous brain-associated disorders currently remains unrealized due to serious limitations imposed by the blood-brain-barrier (BBB). The BBB generally allows transport of small molecules, typically <600 daltons with high octanol/water partition coefficients, but denies passage to most larger molecules. However, some receptors present on the BBB allow passage of cognate proteins to the brain. Utilizing such receptor-ligand systems, several investigators have developed methods for delivering proteins to the brain, a critical requirement of which involves covalent linking of the target protein to a carrier entity. Such covalent modifications involve extensive preparative and post-preparative chemistry that poses daunting limitations in the context of delivery to any organ. Here, we report creation of a 36-amino acid peptide transporter, which can transport a protein to the brain after routine intravenous injection of the transporter-protein mixture. No covalent linkage of the protein with the transporter is necessary. A peptide transporter comprising sixteen lysine residues and 20 amino acids corresponding to the LDLR-binding domain of apolipoprotein E (ApoE) was synthesized. Transport of beta-galactosidase, IgG, IgM, and antibodies against amyloid plques to the brain upon iv injection of the protein-transporter mixture was evaluated through staining for enzyme activity or micro single photon emission tomography (micro-SPECT) or immunostaining. Effect of the transporter on the integrity of the BBB was also investigated. The transporter enabled delivery to the mouse brain of functional beta-galactosidase, human IgG and IgM, and two antibodies that labeled brain-associated amyloid beta plaques in a mouse model of Alzheimer's disease. The results suggest the transporter is able to transport most or all proteins to the brain without the need for chemically linking the transporter to a protein. Thus, the approach offers an avenue for rapid clinical evaluation of numerous candidate drugs against neurological diseases including cancer. (299 words).


    • 1 November 2009
      • Vol. 29  (11) , 4317-22

    Preferential expression of the secreted and membrane forms of tumor endothelial marker 7 transcripts in osteosarcoma.

    by Chandralekha Halder, Christian Ossendorf, Avudaiappan Maran, Michael Yaszemski, Mark E Bolander, Bruno Fuchs, Gobinda Sarkar

    High expression of tumor endothelial marker 7 (TEM7) is correlated with osteogenic sarcoma (OS) metastasis and poor survival of patients. The TEM7 gene produces four alternatively spliced transcripts with distinct functional domains; the expression pattern of these transcripts in OS is unknown. mRNA expression was assessed in 5 OS cell lines, 7 normal bone, and 9 OS tumor specimens by reverse transcriptase polymerase chain reaction. All OS cell lines, 6/9 tumors but none of the bone specimens expressed mRNA of TEM7 secreted forms 1 and 2. A total of 3/5 OS cell lines, 8/9 of tumors and 4/7 of bone specimens expressed mRNA of the TEM7 intracellular form. One out of 5 cell lines, 2/7 tumors and none of the bone specimens expressed mRNA of the TEM7 membrane form. The secreted forms had 20-fold higher expression in metastatic (LM7) compared to non-metastatic (SAOS-2) cells. The mRNA of secreted and the membrane forms of TEM7 are preferentially expressed in OS.


  • Open Access

    2-methoxyestradiol-induced cell death in osteosarcoma cells is preceded by cell cycle arrest

    by Avudaiappan Maran, Kristen L. Shogren, Michaela Benedikt, Gobinda Sarkar, Russell T. Turner, Michael J. Yaszemski